Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-center, Randomized, Double-blind, Placebo-controlled, Multiple-ascending-dose Phase Id/IIa Study Evaluating the Safety, Tolerability, and Pharmacokinetics of ZT002 Injection in Adult Chinese Subjects With Type 2 Diabetes Mellitus (T2DM)

NCT07065032 is registered in ClinicalTrials.gov with Beijing QL Biopharmaceutical Co.,Ltd as lead sponsor.

NCT NCT07065032
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07065032 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-center, Randomized, Double-blind, Placebo-controlled, Multiple-ascending-dose Phase Id/IIa Study Evaluating the Safety, Tolerability, and Pharmacokinetics of ZT002 Injection in Adult Chinese Subjects With Type 2 Diabetes Mellitus (T2DM)
Lead sponsor
Beijing QL Biopharmaceutical Co.,Ltd
Phase
Phase 1/2
Overall status
Completed
Start date
February 19, 2024
Completion date
August 5, 2024
Enrollment
27 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

type 2 diabetes